Our Mission

Neuroblastoma cells growing in a "test tube".

Neuroblastoma is a childhood solid tumor cancer that forms in the nervous system outside the brain. It can occur with different degrees of aggression, labeled low-, intermediate-, and high-risk. Approximately 50% of children with neuroblastoma will have high-risk disease, which often reoccurs, or relapses, or becomes resistant to standard therapies and gets worse.

The NANT consortium is a group of 15 Universities and Childrens Hospitals with strong research and treatment programs for neuroblastoma. Working closely together, they test promising new therapies for high-risk and relapsed neuroblastoma. The majority of funding for NANT comes from the National Cancer Institute.

NANT was formed to provide a group of closely collaborating investigators who are linked with laboratory programs developing novel therapies for high-risk neuroblastoma.

NANT conducts clinical trials that test new drugs and new combinations of drugs against high-risk neuroblastoma. Those with promising results will then be considered for more extensive national testing.